| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| NeuroBo Pharmaceuticals, Inc. | Director | Common Stock | 9.07K | $28.4K | $3.13 | Jun 7, 2024 | Direct |
| AGILE THERAPEUTICS INC | Director | Common Stock | 2.07K | $1.76K | $0.85 | Jun 9, 2022 | Direct |
| AGILE THERAPEUTICS INC | Director | Employee Stock Option (Right to Buy) | 807 | Jun 9, 2022 | Direct | ||
| Endo International plc | Executive VP, Global R&D | 2015 Stock Incentive Plan Restricted Stock Units (RSU) | 0 | Jul 15, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| NRBO | NeuroBo Pharmaceuticals, Inc. | Jun 7, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director |
| NRBO | NeuroBo Pharmaceuticals, Inc. | Dec 1, 2023 | 2 | $0 | 4 | Dec 4, 2023 | Director |
| NRBO | NeuroBo Pharmaceuticals, Inc. | Nov 1, 2023 | 0 | $0 | 3 | Nov 2, 2023 | Director |
| ENDPQ | Endo International plc | Jul 15, 2022 | 1 | $0 | 4 | Aug 17, 2022 | Executive VP, Global R&D |
| AGRX | AGILE THERAPEUTICS INC | Jun 9, 2022 | 2 | $0 | 4 | Jun 10, 2022 | Director |
| ENDPQ | Endo International plc | Feb 24, 2022 | 0 | $0 | 3 | Feb 24, 2022 | Executive VP, Global R&D |
| AGRX | AGILE THERAPEUTICS INC | Jun 8, 2021 | 2 | $0 | 4 | Jun 10, 2021 | Director |